By Fineline Cube Kanova Biopharma, a Suzhou-based developer of antibodies focused on autoimmune diseases and oncology, has reportedly raised over RMB 100 million (USD 13.9 million) in a new financing round. The round was led by GTJA Investment, marking a significant capital injection into the company’s pipeline development.
Company Background and Product Pipeline
Founded in 2015, Kanova Bio boasts several product pipelines with intellectual property rights. The company’s core product, XKH004, an IL-17A/F antibody, has concluded Phase II studies in psoriasis and ankylosing spondylitis and entered into a head-to-head Phase III study in June against secukinumab. This advancement demonstrates Kanova Bio’s commitment to advancing treatments for autoimmune diseases.
Clinical Trials and Pipeline Progress
In addition to XKH004, Kanova Bio’s pipeline includes XKH001, an IL-25 inhibitor being developed to treat asthma, and XKH002, a B7S1 monoclonal antibody (mAb) designed to restore and enhance the body’s anti-tumor immune response. Both of these products have obtained clinical trial approvals in the US and China, indicating the company’s global reach and potential impact on the treatment landscape for asthma and cancer patients.-Fineline Info & Tech